about
Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules.Anti-epidermal growth factor receptor siRNA carried by chitosan-transacylated lipid nanocapsules increases sensitivity of glioblastoma cells to temozolomide.Mucus models to evaluate nanomedicines for diffusion.Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.Toward an effective strategy in glioblastoma treatment. Part II: RNA interference as a promising way to sensitize glioblastomas to temozolomide.Models for drug absorption from the small intestine: where are we and where are we going?Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma.How to design the surface of peptide-loaded nanoparticles for efficient oral bioavailability?In vivo evaluation of paclitaxel-loaded lipid nanocapsules after intravenous and oral administration on resistant tumor.Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide.Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas.The adaptation of lipid nanocapsule formulations for blood administration in animals.Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery.Reciprocal competition between lipid nanocapsules and P-gp for paclitaxel transport across Caco-2 cells.Baclofen-loaded microspheres: preparation and efficacy testing in a new rabbit model.Baclofen-loaded microspheres in gel suspensions for intrathecal drug delivery: in vitro and in vivo evaluation.Cytotoxicity and genotoxicity of lipid nanocapsules.Development and characterization of interleukin-18-loaded biodegradable microspheres.Comparison of Raman spectroscopy vs. high performance liquid chromatography for quality control of complex therapeutic objects: model of elastomeric portable pumps filled with a fluorouracil solutionDevelopment and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administrationThe gastrointestinal stability of lipid nanocapsulesStability of micafungin sodium solutions at different concentrations in glass bottles and syringesDesign and stability study of a paediatric oral solution of methotrexate 2 mg/mlDevelopment of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules
P50
Q34528991-052060E5-C085-4D4E-8BB9-D746A0801277Q37671610-E1B14E32-810F-4501-8B13-49D0A97820E3Q38184683-AEB129E1-0BC2-44C4-A67B-BBD3940CBA78Q38368193-4BD06EE0-B14D-4EA3-A2ED-5974456E7101Q38429199-FC5712A0-9BE7-47BC-8C86-E8726809FE00Q38766704-686E60C3-D833-4D70-85C0-B83AADAD836CQ38797804-70129406-8BE2-4F25-B17F-6D5A4B4EECE8Q38801801-FD5646EF-DFBB-4EDA-8F6A-1EBB94FBE049Q38905471-561C948F-6A81-4A06-B451-69E03736877CQ38913880-84EACBCE-2664-4516-8DD6-37131C31C39BQ39129470-1272388C-5A3F-46CE-9C00-E559A7048FCDQ39711149-9D118AE3-EE60-47F8-A371-39527B93E16AQ39847421-1F56BE46-F69E-42B0-8A1C-C65818B7343AQ42910331-BA535779-ABCA-4D1D-AE66-07E3D4DF0844Q43075752-F00689CE-5B14-4A74-95DB-4B3F77167251Q46370486-6730A9C1-9781-46D2-BC34-153247F97F1CQ46557588-F05D287C-A4CB-4FF7-917B-A5563C3C925FQ50182783-7294BDE1-2639-4E34-A93A-AD66C7AA21BAQ51253736-0CA9FD4E-6C2D-42CD-B716-DE946B815F1AQ57164635-90F99861-F16A-48C1-A7B1-EEFEEE16CCABQ83389225-5155419C-67B9-43EA-8B22-BBA212F0EFDAQ84067482-C9ADE048-B189-43A3-BC6E-D9E51EB9A8ECQ85621882-5854B4BD-D347-41DF-989C-00292488799CQ87130020-5390B2FB-74BC-42F2-B5B4-AB87FDC30B1AQ87176426-C4FEDD4B-9A33-4AAC-9AE7-DEC01643FA2B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Frédéric Lagarce
@ast
Frédéric Lagarce
@en
Frédéric Lagarce
@es
Frédéric Lagarce
@nl
Frédéric Lagarce
@sl
type
label
Frédéric Lagarce
@ast
Frédéric Lagarce
@en
Frédéric Lagarce
@es
Frédéric Lagarce
@nl
Frédéric Lagarce
@sl
prefLabel
Frédéric Lagarce
@ast
Frédéric Lagarce
@en
Frédéric Lagarce
@es
Frédéric Lagarce
@nl
Frédéric Lagarce
@sl
P106
P1153
11838926000
P21
P31
P496
0000-0001-7518-0673